natgillin/translations-raw huggingface dataset:
Clinical studies that were conducted excluded patients with AST or ALT &gt; 2.5 × upper limit of normal (ULN), or if due to underlying malignancy, &gt; 5.0 × ULN or with total bilirubin &gt; 1.5 × ULN.
Z realizovaných klinických štúdií boli vylúčení pacienti s hladinou AST alebo ALT &gt; 2,5  ULN (hornej hranice normy (ULN - upper limit of normal)) alebo bolo zvýšenie spôsobené základným malígnym ochorením s &gt; 5  ULN alebo s hladinou celkového bilirubínu &gt; 1,5  ULN.
Clinical trials excluded patients with ECOG performance status &gt; 1 and mucosal melanoma.
Z klinických štúdií boli vylúčení pacienti s výkonnostným stavom podľa ECOG &gt; 1 a slizničným melanómom.
Clinically relevant ADRs reported in ≥1% and &lt; 5% of the ramucirumab plus docetaxel-treated patients in REVEL were hyponatraemia (4.8% ramucirumab plus docetaxel versus 2.4% for placebo plus docetaxel), proteinuria (3.3% ramucirumab plus docetaxel versus 0.8% placebo plus docetaxel) and gastrointestinal perforation (1% ramucirumab plus docetaxel versus 0.3% placebo plus docetaxel).
Klinicky relevantné ADR hlásené u ≥ 1% a &lt; 5 % pacientov liečených ramucirumabom a paklitaxelom v štúdii REVEL boli hyponatrémia (4,8 % pri ramucirumabe s docetaxelom v porovnaní s 2,4 % pri placebe s docetaxelom), proteinúria (3,3 % pri ramucirumabe s docetaxelom v porovnaní s 0,8% placebe s docetaxelom) a gastrointestinálna perforácia (1 % pri ramucirumabe s docetaxelom v porovnaní s 0,3 % pri placebe s docetaxelom).
Clinically relevant ADRs reported in ≥1% and &lt; 5% of the ramucirumab plus paclitaxel-treated patients in RAINBOW were gastrointestinal perforation (1.2% ramucirumab plus paclitaxel versus 0.3% for placebo plus paclitaxel) and sepsis (3.1% ramucirumab plus paclitaxel versus 1.8% placebo plus paclitaxel).
Klinicky relevantné ADR hlásené u ≥ 1% a &lt; 5 % pacientov liečených ramucirumabom a paklitaxelom v štúdii RAINBOW boli gastrointestinálna perforácia (1,2 % pri ramucirumabe a paklitaxeli v porovnaní s 0,3 % pri placebe a paklitaxeli) a sepsa (3,1 % pri ramucirumabe a paklitaxeli v porovnaní s 1,8 % pri placebe a paklitaxeli).
Clinically relevant ADRs reported in ≥1% and &lt; 5% of the ramucirumab treated patients in REGARD were: neutropenia, arterial thromboembolic events (see sections 4.2 and 4.4), intestinal obstruction, epistaxis, and rash.
Klinicky relevantné ADR hlásené u ≥ 1% a &lt; 5% pacientov liečených ramucirumabom v štúdii REGARD boli: neutropénia, cievne tromboembolické príhody (pozri časti 4.2 a 4.4), intestinálna obštrukcia, krvácanie z nosa a vyrážka.
clinically relevant bradycardia (persistent heart rate &lt; 50 bpm);
klinicky relevantnou bradykardiou (stála srdcová frekvencia &lt; 50 úderov za min);
Clinically relevant CTC toxicities that were reported in &lt; 1 % of the patients that were randomly assigned to pemetrexed include supraventricular arrhythmias.
Klinicky relevantná toxicita zaznamenaná u &lt; 1 % pacientov, ktorí boli randomizovaní na liečbu cisplatinou a pemetrexedom, zahŕňa: zvýšenie GMT, bolesť na hrudi, arytmiu a motorickú neuropatiu.
Clinically relevant CTC toxicities that were reported in &lt; 1 % of the patients that were randomly assigned to pemetrexed include supraventricular arrhythmias.
Klinicky relevantné CTC toxicity, zaznamenané u &lt; 1 % pacientov, ktorí boli randomizovaní na liečbu pemetrexedom, sú: supraventrikulárne arytmie.
Clinically relevant CTC toxicities that were reported in &lt; 1 % of the patients that were randomly assigned to pemetrexed include supraventricular arrhythmias.
Klinicky relevantné kritériá bežnej toxicity, zaznamenané u &lt; 1 % pacientov, ktorí boli randomizovaní na liečbu pemetrexedom, sú: supraventrikulárne arytmie.
Clinically relevant CTC toxicities that were reported in &lt; 1 % of the patients that were randomly assigned to pemetrexed include supraventricular arrhythmias.
Klinicky relevantné prejavy toxicity podľa kritérií bežnej toxicity, zaznamenané u &lt; 1 % pacientov, ktorí boli randomizovaní na liečbu pemetrexedom, sú: supraventrikulárne arytmie.
Clinically relevant CTC toxicities that were reported in &lt; 1 % of the patients that were randomly assigned to pemetrexed include supraventricular arrhythmias.
Klinicky významné prejavy toxicity s ohľadom na pohlavie boli rovnaké ako v celkovej populácii u pacientov užívajúcich pemetrexed s cisplatinou.
Clinically relevant CTC toxicities that were reported in &lt; 1 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include arrhythmia and motor neuropathy.
Klinicky relevantné CTC toxicity, zaznamenané u &lt; 1 % pacientov, ktorí boli randomizovaní na liečbu s cisplatinou a pemetrexedom, sú: arytmia a motorická neuropatia.
Clinically relevant CTC toxicities that were reported in &lt; 1 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include arrhythmia and motor neuropathy.
Klinicky relevantné CTC toxicity, zaznamenané u &lt; 1 % pacientov, ktorí boli randomizovaní na liečbu pemetrexedom, sú: supraventrikulárne arytmie.
Clinically relevant CTC toxicities that were reported in &lt; 1 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include arrhythmia and motor neuropathy.
Klinicky relevantné kritériá bežnej toxicity zaznamenané u &lt; 1 % pacientov, ktorí boli randomizovaní na liečbu cisplatinou a pemetrexedom, sú: arytmia a motorická neuropatia.
Clinically relevant CTC toxicities that were reported in &lt; 1 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include arrhythmia and motor neuropathy.
Klinicky relevantné kritériá bežnej toxicity, zaznamenané u &lt; 1 % pacientov, ktorí boli randomizovaní na liečbu s cisplatinou a pemetrexedom, sú: arytmia a motorická neuropatia.
Clinically relevant CTC toxicities that were reported in &lt; 1 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include arrhythmia and motor neuropathy.
Klinicky relevantné kritériá bežnej toxicity, zaznamenané u &lt; 1 % pacientov, ktorí boli randomizovaní na liečbu pemetrexedom, sú: supraventrikulárne arytmie.
Clinically relevant CTC toxicities that were reported in &lt; 1 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include arrhythmia and motor neuropathy.
Klinicky relevantné prejavy toxicity podľa kritérií bežnej toxicity (CTC), zaznamenané u &lt; 1 % pacientov, ktorí boli randomizovaní na liečbu s cisplatinou a pemetrexedom, sú: arytmia a motorická neuropatia.
Clinically relevant CTC toxicities that were reported in &lt; 1% of the patients that were randomly assigned to pemetrexed include supraventricular arrhythmias.
Klinicky relevantné kritériá bežnej toxicity, zaznamenané u &lt; 1 % pacientov, ktorí boli randomizovaní na liečbu pemetrexedom, sú: supraventrikulárne arytmie.
Clinically relevant CTC toxicities that were reported in &lt; 1% of the patients that were randomly assigned to receive cisplatin and pemetrexed include arrhythmia and motor neuropathy.
Klinicky relevantné kritériá bežnej toxicity, zaznamenané u &lt; 1 % pacientov, ktorí boli randomizovaní na liečbu s cisplatinou a pemetrexedom, sú: arytmia a motorická neuropatia.
Clinically relevant CTC toxicities that were reported in ≥ 1 % and &lt; 5 % of the patients that were randomly assigned to pemetrexed include: infection without neutropenia, febrile neutropenia, allergic reaction/hypersensitivity, increased creatinine, motor neuropathy, sensory neuropathy, erythema multiforme, and abdominal pain.
Klinicky relevantná toxicita zaznamenaná u &lt; 1 % pacientov, ktorí boli randomizovaní na liečbu cisplatinou a pemetrexedom, zahŕňa: zvýšenie GGT, bolesť na hrudi, arytmiu a motorickú neuropatiu.
Clinically relevant CTC toxicities that were reported in ≥ 1 % and &lt; 5 % of the patients that were randomly assigned to pemetrexed include: infection without neutropenia, febrile neutropenia, allergic reaction/hypersensitivity, increased creatinine, motor neuropathy, sensory neuropathy, erythema multiforme, and abdominal pain.
Klinicky relevantná toxicita zaznamenaná u ≥ 1 % a &lt; 5 % pacientov, ktorí boli randomizovaní na liečbu s cisplatinou a pemetrexedom, zahŕňa: zvýšenie AST, zvýšenie ALT, infekciu, febrilnú neutropéniu, renálne zlyhanie, pyrexiu, dehydratáciu, konjunktivitídu a pokles klírensu kreatinínu.
Clinically relevant CTC toxicities that were reported in ≥ 1 % and &lt; 5 % of the patients that were randomly assigned to pemetrexed include: infection without neutropenia, febrile neutropenia, allergic reaction/hypersensitivity, increased creatinine, motor neuropathy, sensory neuropathy, erythema multiforme, and abdominal pain.
Klinicky relevantné CTC toxicity, zaznamenané u ≥ 1 % a ≤ 5 % pacientov, ktorí boli randomizovaní na liečbu s pemetrexedom, sú: infekcia bez neutropénie, febrilná neutropénia, alergická reakcia/precitlivenosť, zvýšený kreatinín, motorická neuropatia, senzorická neuropatia, erythema multiforme a abdominálna bolesť.
Clinically relevant CTC toxicities that were reported in ≥ 1 % and &lt; 5 % of the patients that were randomly assigned to pemetrexed include: infection without neutropenia, febrile neutropenia, allergic reaction/hypersensitivity, increased creatinine, motor neuropathy, sensory neuropathy, erythema multiforme, and abdominal pain.
Klinicky relevantné kritériá bežnej toxicity, zaznamenané u - ≥ 1 % a &lt; 5 % pacientov, ktorí boli randomizovaní na liečbu s pemetrexedom, sú: infekcia bez neutropénie, febrilná neutropénia, alergická reakcia/precitlivenosť, zvýšený kreatinín, motorická neuropatia, senzorická neuropatia, erythema multiforme a abdominálna bolesť.
Clinically relevant CTC toxicities that were reported in ≥ 1 % and &lt; 5 % of the patients that were randomly assigned to pemetrexed include: infection without neutropenia, febrile neutropenia, allergic reaction/hypersensitivity, increased creatinine, motor neuropathy, sensory neuropathy, erythema multiforme, and abdominal pain.
Klinicky relevantné kritériá bežnej toxicity, zaznamenané u - ≥ 1 % a &lt; 5 % pacientov, ktorí boli randomizovaní na liečbu s pemetrexedom, sú: infekcia bez neutropénie, febrilná neutropénia, alergická reakcia/precitlivenosť, zvýšený kreatinín, motorická neuropatia, senzorická neuropatia, multiformný erytém a abdominálna bolesť.
Clinically relevant CTC toxicities that were reported in ≥ 1 % and &lt; 5 % of the patients that were randomly assigned to pemetrexed include: infection without neutropenia, febrile neutropenia, allergic reaction/hypersensitivity, increased creatinine, motor neuropathy, sensory neuropathy, erythema multiforme, and abdominal pain.
Klinicky relevantné kritériá bežnej toxicity, zaznamenané u ≥ 1 % a &lt; 5 % pacientov, ktorí boli randomizovaní na liečbu s pemetrexedom, sú: infekcia bez neutropénie, febrilná neutropénia, alergická reakcia/precitlivenosť, zvýšený kreatinín, motorická neuropatia, senzorická neuropatia, erythema multiforme a abdominálna bolesť.
Clinically relevant CTC toxicities that were reported in ≥ 1 % and &lt; 5 % of the patients that were randomly assigned to pemetrexed include: infection without neutropenia, febrile neutropenia, allergic reaction/hypersensitivity, increased creatinine, motor neuropathy, sensory neuropathy, erythema multiforme, and abdominal pain.
Klinicky relevantné kritériá bežnej toxicity, zaznamenané u ≥ 1 % a &lt; 5 % pacientov, ktorí boli randomizovaní na liečbu s pemetrexedom, sú: infekcia bez neutropénie, febrilná neutropénia, alergická reakcia/precitlivenosť, zvýšený kreatinín, motorická neuropatia, senzorická neuropatia, multiformný erytém a abdominálna bolesť.
Clinically relevant CTC toxicities that were reported in ≥ 1 % and &lt; 5 % of the patients that were randomly assigned to pemetrexed include: infection without neutropenia, febrile neutropenia, allergic reaction/hypersensitivity, increased creatinine, motor neuropathy, sensory neuropathy, erythema multiforme, and abdominal pain.
Klinicky relevantné prejavy toxicity podľa kritérií bežnej toxicity, zaznamenané u ≥ 1 % a &lt; 5 % pacientov, ktorí boli randomizovaní na liečbu s pemetrexedom, sú: infekcia bez neutropénie, febrilná neutropénia, alergická reakcia/precitlivenosť, zvýšený kreatinín, motorická neuropatia, senzorická neuropatia, erythema multiforme a abdominálna bolesť.
Clinically relevant CTC toxicities that were reported in ≥ 1 % and &lt; 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: renal failure, infection, pyrexia, febrile neutropenia, increased AST, ALT, and GGT, urticaria and chest pain.
Klinicky relevantné CTC toxicity, zaznamenané u ≥ 1 % a ≤ 5 % pacientov, ktorí boli náhodne vybratí (randomizovaní) na liečbu s cisplatinou a pemetrexedom, sú: renálne zlyhanie, infekcia, pyrexia, febrilná neutropénia, zvýšené AST, ALT a GMT, urtikária a bolesť na hrudi.
Clinically relevant CTC toxicities that were reported in ≥ 1 % and &lt; 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: renal failure, infection, pyrexia, febrile neutropenia, increased AST, ALT, and GGT, urticaria and chest pain.
Klinicky relevantné CTC toxicity, zaznamenané u ≥ 1 % a ≤ 5 % pacientov, ktorí boli randomizovaní na liečbu s pemetrexedom, sú: infekcia bez neutropénie, febrilná neutropénia, alergická reakcia/precitlivenosť, zvýšený kreatinín, motorická neuropatia, senzorická neuropatia, erythema multiforme a abdominálna bolesť.
Clinically relevant CTC toxicities that were reported in ≥ 1 % and &lt; 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: renal failure, infection, pyrexia, febrile neutropenia, increased AST, ALT, and GGT, urticaria and chest pain.
Klinicky relevantné kritériá bežnej toxicity, zaznamenané u - ≥ 1 % a &lt; 5 % pacientov, ktorí boli náhodne vybratí (randomizovaní) na liečbu s cisplatinou a pemetrexedom, sú: renálne zlyhanie, infekcia, pyrexia, febrilná neutropénia, zvýšené AST, ALT a GMT, urtikária a bolesť na hrudi.
Clinically relevant CTC toxicities that were reported in ≥ 1 % and &lt; 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: renal failure, infection, pyrexia, febrile neutropenia, increased AST, ALT, and GGT, urticaria and chest pain.
Klinicky relevantné kritériá bežnej toxicity, zaznamenané u ≥ 1 % a &lt; 5 % pacientov, ktorí boli náhodne vybratí (randomizovaní) na liečbu cisplatinou a pemetrexedom, sú: renálne zlyhanie, infekcia, pyrexia, febrilná neutropénia, zvýšené AST, ALT a GMT, urtikária a bolesť na hrudi.
Clinically relevant CTC toxicities that were reported in ≥ 1 % and &lt; 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: renal failure, infection, pyrexia, febrile neutropenia, increased AST, ALT, and GGT, urticaria and chest pain.
Klinicky relevantné kritériá bežnej toxicity, zaznamenané u ≥ 1 % a &lt; 5 % pacientov, ktorí boli náhodne vybratí (randomizovaní) na liečbu s cisplatinou a pemetrexedom, sú: renálne zlyhanie, infekcia, pyrexia, febrilná neutropénia, zvýšené AST, ALT a GMT, urtikária a bolesť na hrudi.
Clinically relevant CTC toxicities that were reported in ≥ 1 % and &lt; 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: renal failure, infection, pyrexia, febrile neutropenia, increased AST, ALT, and GGT, urticaria and chest pain.
Klinicky relevantné kritériá bežnej toxicity, zaznamenané u ≥ 1 % a &lt; 5 % pacientov, ktorí boli randomizovaní na liečbu s pemetrexedom, sú: infekcia bez neutropénie, febrilná neutropénia, alergická reakcia/precitlivenosť, zvýšený kreatinín, motorická neuropatia, senzorická neuropatia, erythema multiforme a abdominálna bolesť.
Clinically relevant CTC toxicities that were reported in ≥ 1 % and &lt; 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: renal failure, infection, pyrexia, febrile neutropenia, increased AST, ALT, and GGT, urticaria and chest pain.
Klinicky relevantné prejavy toxicity podľa kritérií bežnej toxicity, zaznamenané u ≥ 1 % a &lt; 5 % pacientov, ktorí boli randomizovaní na liečbu s cisplatinou a pemetrexedom, sú: renálne zlyhanie, infekcia, pyrexia, febrilná neutropénia, zvýšené AST, ALT a GGT, urtikária a bolesť na hrudi.
Clinically relevant CTC toxicities that were reported in ≥ 1 % and ≤ 5 % of the patients that were randomly assigned to pemetrexed include: infection without neutropenia, febrile neutropenia, allergic reaction/hypersensitivity, increased creatinine, motor neuropathy, sensory neuropathy, erythema multiforme, and abdominal pain.
Klinicky relevantné kritériá bežnej toxicity, zaznamenané u ≥ 1 % a &lt; 5 % pacientov, ktorí boli randomizovaní na liečbu s pemetrexedom, sú: infekcia bez neutropénie, febrilná neutropénia, alergická reakcia/precitlivenosť, zvýšený kreatinín, motorická neuropatia, senzorická neuropatia, multiformný erytém a abdominálna bolesť.
Clinically relevant CTC toxicities that were reported in ≥ 1 % and ≤ 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: renal failure, infection, pyrexia, febrile neutropenia, increased AST, ALT, and GGT, urticaria and chest pain.
Klinicky relevantné kritériá bežnej toxicity, zaznamenané u ≥ 1 % a &lt; 5 % pacientov, ktorí boli náhodne vybratí (randomizovaní) na liečbu s cisplatinou a pemetrexedom, sú: renálne zlyhanie, infekcia, pyrexia, febrilná neutropénia, zvýšené AST, ALT a GMT, urtikária a bolesť na hrudi.
Clinically relevant CTC toxicities that were reported in ≥ 1% and ≤ 5% of the patients that were randomly assigned to pemetrexed include: infection without neutropenia, febrile neutropenia, allergic reaction/hypersensitivity, increased creatinine, motor neuropathy, sensory neuropathy, erythema multiforme, and abdominal pain.
Klinicky relevantné kritériá bežnej toxicity, zaznamenané u - ≥ 1 % a &lt; 5 % pacientov, ktorí boli randomizovaní na liečbu s pemetrexedom, sú: infekcia bez neutropénie, febrilná neutropénia, alergická reakcia/precitlivenosť, zvýšený kreatinín, motorická neuropatia, senzorická neuropatia, erythema multiforme a abdominálna bolesť.
Clinically relevant CTC toxicities that were reported in ≥ 1% and ≤ 5% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: renal failure, infection, pyrexia, febrile neutropenia, increased AST, ALT, and GGT, urticaria and chest pain.
Klinicky relevantné kritériá bežnej toxicity, zaznamenané u ≥ 1 % a &lt; 5 % pacientov, ktorí boli náhodne vybratí (randomizovaní) na liečbu s cisplatinou a pemetrexedom, sú: renálne zlyhanie, infekcia, pyrexia, febrilná neutropénia, zvýšené AST, ALT a GMT, urtikária a bolesť na hrudi.
Clinically relevant CTC toxicity that was reported in &lt; 1 % of the patients that were randomly assigned to pemetrexed include: allergic reaction/hypersensitivity, erythema multiforme, supraventricular arrhythmia and pulmonary embolism.
Klinicky relevantná toxicita (podľa CTC) akéhokoľvek stupňa hlásená u &lt; 1 % pacientov randomizovaných na pemetrexed zahŕňa: alergické reakcie/ hypersenzitivitu, multiformný erytém, supraventikulárnu arytmiu a pľúcnu embóliu.
Clinically relevant CTC toxicity that was reported in &lt; 1% of the patients that were randomly assigned to pemetrexed include: allergic reaction/hypersensitivity, erythema multiforme, supraventricular arrhythmia and pulmonary embolism.
Klinicky relevantná toxicita (podľa CTC) akéhokoľvek stupňa hlásená u &lt; 1 % pacientov randomizovaných na pemetrexed zahŕňa: alergické reakcie/ hypersenzitivitu, multiformný erytém, supraventikulárnu arytmiu a pľúcnu embóliu.
Clinically relevant CTC toxicity that was reported in &lt; 1% of the patients that were randomly assigned to pemetrexed include: allergic reaction/hypersensitivity, erythema multiforme, supraventricular arrhythmia and pulmonary embolism.
Klinicky relevantná toxicita (podľa CTC) hlásená u &lt; 1 % pacientov randomizovaných na pemetrexed zahŕňa: alergické reakcie/ hypersenzitivitu, multiformný erytém, supraventikulárnu arytmiu a pľúcnu embóliu.
Clinically relevant CTC toxicity that was reported in &lt; 1% of the patients that were randomly assigned to pemetrexed include: allergic reaction/hypersensitivity, erythema multiforme, supraventricular arrhythmia and pulmonary embolism.
Klinicky relevantné prejavy toxicity podľa kritérií bežnej toxicity (CTC) akéhokoľvek stupňa hlásená u &lt; 1 % pacientov randomizovaných na liečbu pemetrexedom zahŕňa: alergické reakcie/ hypersenzitivitu, erythema multiforme, supraventikulárnu arytmiu a pľúcnu embóliu.
Clinically relevant toxicity that was reported in &lt; 1 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: GGT increase, chest pain, arrhythmia, and motor neuropathy.
Klinicky relevantná toxicita (podľa CTC) akéhokoľvek stupňa hlásená u &lt; 1 % pacientov randomizovaných na pemetrexed zahŕňa: alergické reakcie/ hypersenzitivitu, multiformný erytém, supraventikulárnu arytmiu a pľúcnu embóliu.
Clinically relevant toxicity that was reported in &lt; 1 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: GGT increase, chest pain, arrhythmia, and motor neuropathy.
Klinicky relevantná toxicita zaznamenaná u &lt; 1 % pacientov, ktorí boli randomizovaní na liečbu cisplatinou a pemetrexedom, zahŕňa: zvýšenie GGT, bolesť na hrudi, arytmiu a motorickú neuropatiu.
Clinically relevant toxicity that was reported in &lt; 1 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: GGT increase, chest pain, arrhythmia, and motor neuropathy.
Klinicky relevantná toxicita zaznamenaná u &lt; 1 % pacientov, ktorí boli randomizovaní na liečbu cisplatinou a pemetrexedom, zahŕňa: zvýšenie GMT, bolesť na hrudi, arytmiu a motorickú neuropatiu.
Clinically relevant toxicity that was reported in &lt; 1% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: GGT increase, chest pain, arrhythmia, and motor neuropathy.
Klinicky relevantná toxicita (podľa CTC) hlásená u &lt; 1 % pacientov randomizovaných na pemetrexed zahŕňa: alergické reakcie/ hypersenzitivitu, multiformný erytém, supraventikulárnu arytmiu a pľúcnu embóliu.
Clinically relevant toxicity that was reported in &lt; 1% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: GGT increase, chest pain, arrhythmia, and motor neuropathy.
Klinicky relevantná toxicita zaznamenaná u &lt; 1 % pacientov, ktorí boli randomizovaní na liečbu cisplatinou a pemetrexedom, zahŕňa: zvýšenie GMT, bolesť na hrudi, arytmiu a motorickú neuropatiu.
Clinically relevant toxicity that was reported in &lt; 1% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: GGT increase, chest pain, arrhythmia, and motor neuropathy.
Klinicky relevantná toxicita, ktorá bola hlásená u &lt; 1 % pacientov, ktorí boli randomizovaní na liečbu cisplatinou a pemetrexedom, zahŕňa: zvýšenie GGT, bolesť na hrudi, arytmiu a motorickú neuropatiu.
Clinically relevant toxicity that was reported in ≥ 1 % and ≤ 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.
Klinicky relevantná toxicita zaznamenaná u ≥ 1 % a &lt; 5 % pacientov, ktorí boli randomizovaní na liečbu cisplatinou a pemetrexedom, zahŕňa: zvýšenie AST, zvýšenie ALT, infekciu, febrilnú neutropéniu, renálne zlyhanie, pyrexiu, dehydratáciu, konjunktivitídu a pokles klírensu kreatinínu.
Clinically relevant toxicity that was reported in ≥ 1 % and ≤ 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.
Klinicky relevantná toxicita zaznamenaná u ≥ 1 % a &lt; 5 % pacientov, ktorí boli randomizovaní na liečbu s cisplatinou a pemetrexedom, zahŕňa: zvýšenie AST, zvýšenie ALT, infekciu, febrilnú neutropéniu, renálne zlyhanie, pyrexiu, dehydratáciu, konjunktivitídu a pokles klírensu kreatinínu.